Recently, at the 2022 China Medical Development Conference—widely regarded as the country’s premier medical forum—the Chinese Academy of Medical Sciences (CAMS) released two lists: China’s Major Medical Achievements of the 21st Century and China’s Important Medical Advancements in 2021. As a global innovator in the field of Ventricular Assist Devices (VADs), CH Biomedical’s independently developed CH-VAD (NMPA (A) 20213120987) was included in China’s Important Medical Advancements in 2021.
According to the CAMS News Center, China’s Major Medical Achievements of the 21st Century highlights significant medical and health accomplishments in China since 2000 that demonstrate remarkable scientific, technological, economic, social, and cultural value, and enjoy strong peer recognition. Meanwhile China’s Important Medical Advancements in 2021 focuses on noteworthy medical progress made during the year that shows academic and societal impact, promotes disciplinary development, improves “health promotion, disease prevention, diagnosis, control, treatment, and rehabilitation,” and drives growth in the health sector. For the selection process, a classified evaluation method combining “multidimensional metrics” with “multi-party assessment” was adopted, ensuring unbiased inclusion based on diverse data sources. These included medical research papers published by Chinese researchers in 2021, authorized international patents, newly approved domestic drugs, and newly registered innovative Chinese medical devices. In total, over 276,000 data entries were collected as the basis for selection. Through quantitative analysis, expert review, and comprehensive judgment, 77 candidates were initially identified. Following recommendations by Academic Committee members, review by the Review Committee, and final approval by the Executive Committee, 31 important advancements were ultimately chosen.
CH-VAD is the first domestically developed, fully magnetically levitated VAD in China approved by the National Medical Products Administration (NMPA). It employs a new generation of full magnetic levitation technology, achieving multidisciplinary design optimization by seamlessly integrating the magnetic levitation system with the pump’s internal flow path. Compared to the other widely used fully magnetically levitated VAD, CH-VAD has reached a leading international level in key performance indicators—such as hemocompatibility, surgical invasiveness, and infection prevention. Consequently, CH Biomedical has become an industry benchmark and has been recognized internationally as a pioneer in advancing VAD technology.
A Ventricular Assist Device (VAD) is an implantable medical device with high technological barriers, integrating cutting-edge innovations in mechanical engineering, electronics, software control, fluid dynamics, and biomedical engineering, along with advanced international expertise in device development, management, and manufacturing. After more than a decade of independent R&D, CH Biomedical has established a comprehensive intellectual property portfolio spanning China, the United States, Europe, and Japan. Over three consecutive Five-Year Plans, CH Biomedical’s projects have been designated as key national initiatives—such as the National 863 Program, the National Key R&D Program, and the Science and Technology Support Program of the Jiangsu Provincial Department of Science and Technology.
